This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial
Cheng, Sheung-Tak,
Lau, Rosanna W. L.,
Mak, Emily P. M.,
Ng, Natalie S. S.,
Lam, Linda C. W.,
Fung, Helene H.,
Lai, Julian C. L.,
Kwok, Timothy,
Lee, Diana T. F.
Background: Caregivers of relatives with Alzheimer’s disease are highly stressed and at risk for physical and psychiatric conditions. Interventions are usually focused on providing caregivers with knowledge of dementia, skills, and/or support, to help them cope with the stress. This model, though true to a certain extent, ignores how caregiver stress is construed in the […]
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study
Carlsson, Cynthia M.,
Xu, Guofan,
Wen, Zhifei,
Barnet, Jodi H.,
Blazel, Hanna M.,
Chappell, Richard J.,
Stein, James H.,
Asthana, Sanjay,
Sager, Mark A.,
Alsop, David C.,
Rowley, Howard A.,
Fain, Sean B.,
Johnson, Sterling C.
Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
Blennow, Kaj,
Zetterberg, Henrik,
Rinne, Juha O.,
Salloway, Stephen,
Wei, Jenny,
Black, Ronald,
Grundman, Michael,
Liu, Enchi
Background: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.; Objective: To […]
Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease
Kume, Kazumasa,
Hanyu, Haruo,
Sakurai, Hirofumi,
Takada, Yusuke,
Onuma, Takeshi,
Iwamoto, Toshihiko
Aim: Recent studies have shown that some antihypertensive medications are associated with a significant reduction in the incidence of Alzheimer’s disease (AD). However, it remains uncertain whether antihypertensive drugs may have a preventive effect on cognitive decline in patients with AD. We investigated the effects of telmisartan, an angiotensin II type 1 receptor blocker with […]
Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON)
Hooghiemstra, Astrid M.,
Eggermont, Laura H.P.,
Scheltens, Philip,
van der Flier, Wiesje M.,
Bakker, Jet,
de Greef, Mathieu H. G.,
Koppe, Peter A.,
Scherder, Erik J.A.
Background: Although the development of early-onset dementia is a radical and invalidating experience for both patient and family there are hardly any non-pharmacological studies that focus on this group of patients. One type of a non-pharmacological intervention that appears to have a beneficial effect on cognition in older persons without dementia and older persons at […]